Johnson & Johnson places COVID-19 trial on pause after ‘unexplained illness’

  • Johnson & Johnson places COVID-19 trial on pause after ‘unexplained illness’

Johnson & Johnson places COVID-19 trial on pause after ‘unexplained illness’

The study of Johnson & Johnson's Covid-19 vaccine has been paused due to an unexplained illness in a study participant.

It says an independent panel will be reviewing and evaluating the participant's illness before a decision is made on whether to resume the trials. The company declined to provide further details. It will ban any content that contradicts information about those vaccines from the World Health Organization (WHO) or local health authorities, the company said in a blog post.

"We need to increase production of our first and now our second vaccine, first of all we should supply the domestic market", Mr Putin said, adding that Russian Federation will also work with foreign partners to make the inoculations.

Illnesses, even those that are serious, "are an expected part of any clinical study, especially large studies", Johnson & Johnson said, and a study's pause "is a standard component of a clinical trial protocol". "We must save lives with the tools we have at hand", Tedros said. "In a small village, there are a lot of medical events that happen".

Drugmaker Pfizer has plans to start testing its experimental coronavirus vaccine in children as young as 12, and parents have already expressed interest in enrolling their kids, the researcher helping lead the trial told CNN Tuesday.

Early trials of the latest vaccine on 100 volunteers were successful, Putin said.

The FDA noted that a vaccine candidate must be at least 50% effective to receive emergency use authorization.

Russian President Vladimir Putin has announced the approval of a second new coronavirus vaccine in as many months - but neither has completed the kind of extensive and rigorous three-phase trials required in the U.S. "We also know that preventing this disease could require multiple vaccines and we're investing in those that we believe have the greatest potential for success".

The recruitment for phase three trial has been suspended as a precaution.